Enzyme‐Triggered l ‐ α / d ‐Peptide Hydrogels as a Long‐Acting Injectable Platform for Systemic Delivery of HIV/AIDS Drugs
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202203198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Sophie M Coulter und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast, Co. Antrim, Northern Ireland, BT9 7BL, UK. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Engineering and Physical Sciences Research Council, Medical Research Council Canada.
Abstract (Originalsprache)
Eradicating HIV/AIDS by 2030 is a central goal of the World Health Organization. Patient adherence to complicated dosage regimens remains a key barrier. There is a need for convenient long‐acting formulations that deliver drugs over sustained periods. This paper presents an alternative platform, an injectable in situ forming hydrogel implant to deliver a model antiretroviral drug (zidovudine [AZT]) over 28 days. The formulation is a self‐assembling ultrashort d or l ‐ α peptide hydrogelator, namely phosphorylated (naphthalene‐2‐ly)‐acetyl‐diphenylalanine‐lysine‐tyrosine‐OH (NapFFKY[p]‐OH), covalently conjugated to zidovudine via an ester linkage. Rheological analysis demonstrates phosphatase enzyme instructed self‐assembly, with hydrogels forming within minutes. Small angle neutron scattering data suggest hydrogels form narrow radius (≈2 nm), large length fibers closely fitting the flexible cylinder elliptical model. d ‐Peptides are particularly promising for long‐acting delivery, displaying protease resistance for 28 days. Drug release, via hydrolysis of the ester linkage, progress under physiological conditions (37 °C, pH 7.4, H 2 O). Subcutaneous administration of Napffk(AZT)Y[p]G‐OH in Sprague Dawley rats demonstrate zidovudine blood plasma concentrations within the half maximal inhibitory concentration (IC 50 ) range (30–130 ng mL −1 ) for 35 days. This work is a proof‐of‐concept for the development of a long‐acting combined injectable in situ forming peptide hydrogel implant. These products are imperative given their potential impact on society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast, Co. Antrim, Northern Ireland, BT9 7BL, UK.
- School of Chemistry, University of Glasgow, Joseph Black Building, Glasgow, Scotland, G12 8QQ, UK.
- School of Computing, Engineering and Built Environment, Glasgow Caledonian University, Glasgow, Scotland, G4 0BA, UK.
- Large Scale Structures Group, Institut Laue - Langevin, 71 Avenue des Martyrs, CS 20156, Grenoble Cedex 9, 38042, France.
ORCID-Profile: Garry Laverty
Förderung
- Wellcome Trust
- Engineering and Physical Sciences Research Council
- Medical Research Council Canada
- Invest Northern Ireland
Zitieren
APA
Coulter, S. M., Pentlavalli, S., Vora, L. K., An, Y., Cross, E. R., Peng, K., McAulay, K., Schweins, R., Donnelly, R. F., McCarthy, H. O., & Laverty, G. (2023). Enzyme‐Triggered l ‐ α / d ‐Peptide Hydrogels as a Long‐Acting Injectable Platform for Systemic Delivery of HIV/AIDS Drugs. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202203198
Vancouver
Coulter SM, Pentlavalli S, Vora LK, An Y, Cross ER, Peng K, et al. Enzyme‐Triggered l ‐ α / d ‐Peptide Hydrogels as a Long‐Acting Injectable Platform for Systemic Delivery of HIV/AIDS Drugs. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202203198
BibTeX
@article{Coulter2023,
author = {Coulter, Sophie M and Pentlavalli, Sreekanth and Vora, Lalitkumar K and An, Yuming and Cross, Emily R and Peng, Ke and McAulay, Kate and Schweins, Ralf and Donnelly, Ryan F and McCarthy, Helen O and Laverty, Garry},
title = {Enzyme‐Triggered l ‐ α / d ‐Peptide Hydrogels as a Long‐Acting Injectable Platform for Systemic Delivery of HIV/AIDS Drugs},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202203198}
}
EUVIMED